The seed and soil hypothesis revisited: Current state of knowledge of inherited genes on prognosis in breast cancer

Cancer Treatment Reviews

Volumn 40, Issue 2, 2014, Pages 293-299

  Ribelles, Nuria ^a   Santonja, Angela ^a   Pajares, Bella ^a   Llácer, Casilda ^a   Alba, Emilio ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

Author keywords

Breast cancer; Gene expression; Genetic background; Metastasis; Polymorphism; Tumor stroma

Indexed keywords

TUMOR MARKER;

BREAST CANCER; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; FAMILY ASSESSMENT; FAMILY HISTORY; FAMILY RELATION; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GENETIC PREDISPOSITION; GENETIC REGULATION; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; METASTASIS; NONHUMAN; ONCOGENE; REVIEW; RISK ASSESSMENT;

BREAST CANCER; GENE EXPRESSION; GENETIC BACKGROUND; METASTASIS; POLYMORPHISM; TUMOR STROMA;

ANIMALS; BREAST NEOPLASMS; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LYMPHATIC METASTASIS; MEDICAL HISTORY TAKING; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84888288653     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2013.09.010     Document Type: Review

References (78)

1. Liotta L.A., Stetler-Stevenson W.G. Principles of molecular cell biology of cancer 1993, JB Lippincott, Philadelphia, PA. 4th ed.
2. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
3. Fidler I.J. Selection of successive tumour lines for metastasis. Nat New Biol 1973, 242:148-149.
4. Fidler I.J., Kripke M.L. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977, 197:893-895.
5. Giavazzi R., Alessandri G., Spreafico F., Garattini S., Mantovani A. Metastasizing capacity of tumour cells from spontaneous metastases of transplanted murine tumours. Br J Cancer 1980, 42:462-472.
6. Vaage J. Metastasizing potentials of mouse mammary tumors and their metastases. Int J Cancer 1988, 41:855-858.
7. Weiss L. Metastatic inefficiency. Adv Cancer Res 1990, 54:159-211.
8. Kerbel R.S., Frost P., Liteplo R., Carlow D.A., Elliott B.E. Possible epigenetic mechanisms of tumor progression: induction of high-frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5-azacytidine treatment. J Cell Physiol Suppl 1984, 3:87-97.
9. Olsson L., Forchhammer J. Induction of the metastatic phenotype in a mouse tumor model by 5-azacytidine, and characterization of an antigen associated with metastatic activity. Proc Natl Acad Sci USA 1984, 81:3389-3393.
10. Frost P., Kerbel R.S., Hunt B., Man S., Pathak S. Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2'-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression. Cancer Res 1987, 47:2690-2695.
11. Pawelek J.M. Tumour-cell fusion as a source of myeloid traits in cancer. Lancet Oncol 2005, 6:988-993.
12. Chakraborty A., Lazova R., Davies S., Backvall H., Ponten F., Brash D., et al. Donor DNA in a renal cell carcinoma metastasis from a bone marrow transplant recipient. Bone Marrow Transplant 2004, 34:183-186.
13. Yilmaz Y., Lazova R., Qumsiyeh M., Cooper D., Pawelek J. Donor Y chromosome in renal carcinoma cells of a female BMT recipient: visualization of putative BMT-tumor hybrids by FISH. Bone Marrow Transplant 2005, 35:1021-1024.
14. Andersen T.L., Boissy P., Sondergaard T.E., Kupisiewicz K., Plesner T., Rasmussen T., et al. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership?. J Pathol 2007, 211:10-17.
15. Garcia-Olmo D.C., Ruiz-Piqueras R., Garcia-Olmo D. Circulating nucleic acids in plasma and serum (CNAPS) and its relation to stem cells and cancer metastasis: state of the issue. Histol Histopathol 2004, 19:575-583.
16. Bergsmedh A., Szeles A., Henriksson M., Bratt A., Folkman M.J., Spetz A.L., et al. Horizontal transfer of oncogenes by uptake of apoptotic bodies. Proc Natl Acad Sci USA 2001, 98:6407-6411.
17. Dontu G., Al-Hajj M., Abdallah W.M., Clarke M.F., Wicha M.S. Stem cells in normal breast development and breast cancer. Cell Prolif 2003, 36(Suppl. 1):59-72.
18. Dontu G., El-Ashry D., Wicha M.S. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab 2004, 15:193-197.
19. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009, 360:790-800.
20. Bernards R., Weinberg R.A. A progression puzzle. Nature 2002, 418:823.
21. Ramaswamy S., Ross K.N., Lander E.S., Golub T.R. A molecular signature of metastasis in primary solid tumors. Nat Genet 2003, 33:49-54.
22. Kerbel R.S., Waghorne C., Korczak B., Lagarde A., Breitman M.L. Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications. Cancer Surv 1988, 7:597-629.
23. Paget S. The distribution of secondary growths in cancer of the breast. Lancet 1889, 133:571-573.
24. Kang Y., Siegel P.M., Shu W., Drobnjak M., Kakonen S.M., Cordon-Cardo C., et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549.
25. Minn A.J., Gupta G.P., Siegel P.M., Bos P.D., Shu W., Giri D.D., et al. Genes that mediate breast cancer metastasis to lung. Nature 2005, 436:518-524.
26. Bos P.D., Zhang X.H., Nadal C., Shu W., Gomis R.R., Nguyen D.X., et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009.
27. Hunter K.W., Crawford N.P., Alsarraj J. Mechanisms of metastasis. Breast Cancer Res 2008, 10(Suppl. 1):S2.
28. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
29. Topfer K., Kempe S., Muller N., Schmitz M., Bachmann M., Cartellieri M., et al. Tumor evasion from T cell surveillance. J Biomed Biotechnol 2011, 2011:918471.
30. Vesely M.D., Kershaw M.H., Schreiber R.D., Smyth M.J. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011, 29:235-271.
31. Guy C.T., Cardiff R.D., Muller W.J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992, 12:954-961.
32. Lifsted T., Le Voyer T., Williams M., Muller W., Klein-Szanto A., Buetow K.H., et al. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998, 77:640-644.
33. Hunter K. Host genetics influence tumour metastasis. Nat Rev Cancer 2006, 6:141-146.
34. Lancaster M., Rouse J., Hunter K.W. Modifiers of mammary tumor progression and metastasis on mouse chromosomes 7, 9, and 17. Mamm Genome 2005, 16:120-126.
35. Crawford N.P., Alsarraj J., Lukes L., Walker R.C., Officewala J.S., Yang H.H., et al. Bromodomain 4 activation predicts breast cancer survival. Proc Natl Acad Sci USA 2008, 105:6380-6385.
36. Crawford N.P., Qian X., Ziogas A., Papageorge A.G., Boersma B.J., Walker R.C., et al. Rrp1b, a new candidate susceptibility gene for breast cancer progression and metastasis. PLoS Genet 2007, 3:e214.
37. Crawford N.P., Ziogas A., Peel D.J., Hess J., Anton-Culver H., Hunter K.W. Germline polymorphisms in SIPA1 are associated with metastasis and other indicators of poor prognosis in breast cancer. Breast Cancer Res 2006, 8:R16.
38. Lukes L., Crawford N.P., Walker R., Hunter K.W. The origins of breast cancer prognostic gene expression profiles. Cancer Res 2009, 69:310-318.
39. Hartman M., Lindstrom L., Dickman P.W., Adami H.O., Hall P., Czene K. Is breast cancer prognosis inherited?. Breast Cancer Res 2007, 9:R39.
40. Hemminki K., Ji J., Forsti A., Sundquist J., Lenner P. Survival in breast cancer is familial. Breast Cancer Res Treat 2008, 110:177-182.
41. Hemminki K., Sundquist J., Brandt A. Familial mortality and familial incidence in cancer. J Clin Oncol 2011, 29:712-718.
42. Lindstrom L.S., Hall P., Hartman M., Wiklund F., Gronberg H., Czene K. Familial concordance in cancer survival: a Swedish population-based study. Lancet Oncol 2007, 8:1001-1006.
43. Ewertz M., Jensen M.B., Gunnarsdottir K.A., Hojris I., Jakobsen E.H., Nielsen D., et al. Effect of obesity on prognosis after early-stage breast cancer. J Clin Oncol 2011, 29:25-31.
44. Verkooijen H.M., Hartman M., Usel M., Benhamou S., Neyroud-Caspar I., Czene K., et al. Breast cancer prognosis is inherited independently of patient, tumor and treatment characteristics. Int J Cancer 2012, 130:2103-2110.
45. Foulkes W.D., Stefansson I.M., Chappuis P.O., Begin L.R., Goffin J.R., Wong N., et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482-1485.
46. Haffty B.G., Yang Q., Reiss M., Kearney T., Higgins S.A., Weidhaas J., et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006, 24:5652-5657.
47. Lee L.J., Alexander B., Schnitt S.J., Comander A., Gallagher B., Garber J.E., et al. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers. Cancer 2011, 3093-3100.
48. Millikan R.C., Newman B., Tse C.K., Moorman P.G., Conway K., Dressler L.G., et al. Epidemiology of basal-like breast cancer. Breast Cancer Res Treat 2008, 109:123-139.
49. Phipps A.I., Buist D.S., Malone K.E., Barlow W.E., Porter P.L., Kerlikowske K., et al. Family history of breast cancer in first-degree relatives and triple-negative breast cancer risk. Breast Cancer Res Treat 2011, 126:671-678.
50. Welsh M.L., Buist D.S., Aiello Bowles E.J., Anderson M.L., Elmore J.G., Li C.I. Population-based estimates of the relation between breast cancer risk, tumor subtype, and family history. Breast Cancer Res Treat 2009, 114:549-558.
51. Yang X.R., Sherman M.E., Rimm D.L., Lissowska J., Brinton L.A., Peplonska B., et al. Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007, 16:439-443.
52. Abraham J.E., Harrington P., Driver K.E., Tyrer J., Easton D.F., Dunning A.M., et al. Common polymorphisms in the prostaglandin pathway genes and their association with breast cancer susceptibility and survival. Clin Cancer Res 2009, 15:2181-2191.
53. Azzato E.M., Driver K.E., Lesueur F., Shah M., Greenberg D., Easton D.F., et al. Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort. Breast Cancer Res 2008, 10:R47.
54. Choi J.Y., Lee K.M., Noh D.Y., Ahn S.H., Lee J.E., Han W., et al. Genetic polymorphisms of eNOS, hormone receptor status, and survival of breast cancer. Breast Cancer Res Treat 2006, 100:213-218.
55. Choi J.Y., Lee K.M., Park S.K., Noh D.Y., Ahn S.H., Chung H.W., et al. Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 2005, 14:1090-1095.
56. DeMichele A., Martin A.M., Mick R., Gor P., Wray L., Klein-Cabral M., et al. Interleukin-6 -174G→C polymorphism is associated with improved outcome in high-risk breast cancer. Cancer Res 2003, 63:8051-8056.
57. *2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nat Genet 2008, 40:844-853.
58. Goode E.L., Dunning A.M., Kuschel B., Healey C.S., Day N.E., Ponder B.A., et al. Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res 2002, 62:3052-3057.
59. Grieu F., Li W.Q., Iacopetta B. Genetic polymorphisms in the MMP-2 and MMP-9 genes and breast cancer phenotype. Breast Cancer Res Treat 2004, 88:197-204.
60. Hsieh S.M., Look M.P., Sieuwerts A.M., Foekens J.A., Hunter K.W. Distinct inherited metastasis susceptibility exists for different breast cancer subtypes: a prognosis study. Breast Cancer Res 2009, 11:R75.
61. Iacopetta B., Grieu F., Joseph D. The -174 G/C gene polymorphism in interleukin-6 is associated with an aggressive breast cancer phenotype. Br J Cancer 2004, 90:419-422.
62. Li H., Yao L., Ouyang T., Li J., Wang T., Fan Z., et al. Association of p73 G4C14-to-A4T14 (GC/AT) polymorphism with breast cancer survival. Carcinogenesis 2007, 28:372-377.
63. Lu H., Shu X.O., Cui Y., Kataoka N., Wen W., Cai Q., et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005, 65:5015-5019.
64. Piersma D., Berns E.M., Verhoef-Post M., Uitterlinden A.G., Braakman I., Pols H.A., et al. A common polymorphism renders the luteinizing hormone receptor protein more active by improving signal peptide function and predicts adverse outcome in breast cancer patients. J Clin Endocrinol Metab 2006, 91:1470-1476.
65. Schondorf T., Eisele L., Gohring U.J., Valter M.M., Warm M., Mallmann P., et al. The V109G polymorphism of the p27 gene CDKN1B indicates a worse outcome in node-negative breast cancer patients. Tumour Biol 2004, 25:306-312.
66. Shu X.O., Moore D.B., Cai Q., Cheng J., Wen W., Pierce L., et al. Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 2005, 14:91-97.
67. Tommiska J., Eerola H., Heinonen M., Salonen L., Kaare M., Tallila J., et al. Breast cancer patients with p53 Pro72 homozygous genotype have a poorer survival. Clin Cancer Res 2005, 11:5098-5103.
68. Udler M., Maia A.T., Cebrian A., Brown C., Greenberg D., Shah M., et al. Common germline genetic variation in antioxidant defense genes and survival after diagnosis of breast cancer. J Clin Oncol 2007, 25:3015-3023.
69. Udler M.S., Azzato E.M., Healey C.S., Ahmed S., Pooley K.A., Greenberg D., et al. Common germline polymorphisms in COMT, CYP19A1, ESR1, PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J Cancer 2009, 125:2687-2696.
70. Yu H., Bharaj B., Vassilikos E.J., Giai M., Diamandis E.P. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res Treat 2000, 59:153-161.
71. *1100delC heterozygosity in women with breast cancer associated with early death, breast cancer-specific death, and increased risk of a second breast cancer. J Clin Oncol 2012, 30:4308-4316.
72. Jamshidi M., Schmidt M.K., Dork T., Garcia-Closas M., Heikkinen T., Cornelissen S., et al. Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome. Int J Cancer 2012, 2044-2055.
73. Pharoah P.D., Dunning A.M., Ponder B.A., Easton D.F. Association studies for finding cancer-susceptibility genetic variants. Nat Rev Cancer 2004, 4:850-860.
74. Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., et al. Finding the missing heritability of complex diseases. Nature 2009, 461:747-753.
75. Azzato E.M., Tyrer J., Fasching P.A., Beckmann M.W., Ekici A.B., Schulz-Wendtland R., et al. Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survival. J Natl Cancer Inst 2010, 102:650-662.
76. Azzato E.M., Pharoah P.D., Harrington P., Easton D.F., Greenberg D., Caporaso N.E., et al. A genome-wide association study of prognosis in breast cancer. Cancer Epidemiol Biomarkers Prev 2010, 19:1140-1143.
77. Shu X.O., Long J., Lu W., Li C., Chen W.Y., Delahanty R., et al. Novel genetic markers of breast cancer survival identified by a genome-wide association study. Cancer Res 2012, 72:1182-1189.
78. Rafiq S., Tapper W., Collins A., Khan S., Politopoulos I., Gerty S., et al. Identification of inherited genetic variations influencing prognosis in early onset breast cancer. Cancer Res 2013, 1883-1891.